Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Autor:	Brahmer JR; Department of Oncology and the Thoracic Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland, USA., Abu-Sbeih H; Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA., Ascierto PA; Unit of Melanoma Cancer Immunotherapy and Innovative Therapy, National Tumour Institute IRCCS Fondazione 'G. Pascale', Napoli, Italy., Brufsky J; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Cappelli LC; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Cortazar FB; Massachusetts General Hospital, Boston, Massachusetts, USA.; New York Nephrology Vasculitis and Glomerular Center, Albany, New York, USA., Gerber DE; Department of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Hamad L; Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Hansen E; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Johnson DB; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA., Lacouture ME; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Masters GA; Department of Medicine, Helen F. Graham Cancer Center, Newark, Delaware, USA., Naidoo J; Department of Oncology and the Thoracic Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland, USA.; Department of Oncology, Beaumont Hospital Dublin, The Royal College of Surgeons of Ireland, Dublin, Ireland., Nanni M; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Perales MA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Santomasso BD; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Shanbhag SP; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Cancer Specialist of North Florida, Fleming Island, Florida, USA., Sharma R; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Skondra D; Department of Ophthalmology and Visual Science, University of Chicago Medical Center, Chicago, Illinois, USA., Sosman JA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical Center, Chicago, Illinois, USA., Turner M; Department of Oncology and the Thoracic Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland, USA., Ernstoff MS; Division of Cancer Treatment & Diagnosis, National Cancer Institute, Rockville, Maryland, USA marc.ernstoff@nih.gov.
Jazyk:	angličtina
Zdroj:	Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Jun; Vol. 9 (6).
DOI:	10.1136/jitc-2021-002435
Abstrakt:	Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients. Competing Interests: Competing interests: PAA—Contracted research: Bristol-Myers Squibb, Roche, Array; Consulting fees: Bristol-Myers Squibb, Roche, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Medimmune, Sindax, AstraZeneca, Sun Pharma, Sanofy, Idera, Ultimovacs, Sandox, Immunocore, 4sc, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron; Travel support: MSD. JRB—Contracted research: AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, RAPT Therapeutics, Inc, Revolution Medicines; Consulting fees: Amgen, Bristol-Myers Squibb, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, Regeneron; Data and safety monitoring board/committees: GlaxoSmithKline, Sanofi. JB—Partner consulting fees: AstraZeneca, Merck, Roche, Pfizer, Lilly, Daiichi, Seattle Genetics, Novartis. LCC—Consulting fees: AbbVie; Contracted research: Bristol-Myers Squibb, Merck, EMD Serono, Alkermes, Iovance, Merrimack, National Cancer Institute. DEG—Consulting fees: Samsung Bioepis, Catalyst Pharmaceuticals, Bristol-Myers Squibb Steering Committee, G1 Therapeutics; Contracted research: AstraZeneca, BerGenBio, Karyopharm, Bristol-Myers Squibb Steering Committee; Ownership interest: Gilead. DBJ—Consulting fees: Bristol-Myers Squibb, Catalyst Biopharma, Iovance, Jansen, Merck, Novartis, Oncosec; Contracted research: Bristol-Myers Squibb, Incyte. MEL—Contracted research: Veloce, US Biotest, Lutris, Paxman, Novocure Inc; Grant funding: National Cancer Institute Cancer Center support grant P30 CA008748, National Institute of Arthritis and Musculoskeletal and Skin Diseases grant U01AR0775; Royalty: Legacy Healthcare Services, Apricity Health, Azitra, Inc, Deciphera, Galderma Research and Development, Johnson and Johnson, NCODA, Novocure Inc, Kyowa Kirin Inc, Loxo, Merck Sharp and Dohme Corporation, Janssen Research & Development, Menlo Therapeutics, Novartis Pharmaceuticals Corporation, QED Therapeutics, F. Hoffmann-La Roche AG, Amgen Inc, AstraZeneca Pharmceuticals, Genentech Inc, Seattle Genetics, Lutris, Paxman Coolers, OnQuality Pharmaceuticals Ltd, Takeda Millenium. JN—Consulting fees: AstraZeneca, Bristol-Myers Squibb, Merck, Roche/Genentech; Contracted research: AstraZeneca, Merck; Non-CME services: Merck, Bristol-Myers Squibb, AstraZeneca. M-AP—Consulting fees: AbbVie, Bellicum, Celgene, Bristol-Myers Squibb, Incyte, Kite/Gilead, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda; Contracted research: Incyte, Kite/Gilead and Miltenyi Biotec; Ownership interest: NexImmune Member, DSMBs for Cidara Therapeutics, Servier and Medigene. IP—Consulting fees: Merck, Amgen; Ownership interest: Celldex; Partner ownership: Celldex. BDS—Consulting fees: Kite/Gilead, Juno/Celgene; Contracted research: ADC Therapeutics; NPI: 1215164884. SPS—Consulting fees: Takeda, GSK, Kura, Celgene, Daiichi-Sankyo. DS—Scientific advisory board: Allergan, Alimera, Biogen. JAS—Consulting fees: Array, Nektar, Bristol-Myers Squibb, Iovance, Curis; Contracted research: Bristol-Myers Squibb, Corvus, Caltera. HA-S, FBC, MSE, LH, EH, GAM, MN, RS, MT—Nothing to disclose. SITC staff: SMW—Shares owned: Pacific Biosciences of California Inc, Editas Medicine. EG, AK, BL, LL—Nothing to disclose. (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu